# BioCardia, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/BioCardia, Inc.).

## Overview

BioCardia, Inc. is a U.S.-based clinical-stage cardiovascular biotherapeutics company focused on catheter-based delivery systems and cell therapy candidates for heart failure and arrhythmia-related procedures. Its platform centers on the Helix transendocardial delivery system, Morph DNA steerable introducers, and the CardiAMP autologous cell therapy program. The company also develops fusion imaging technology for cardiac biotherapeutic delivery and biopsy, including through a collaboration with CART-Tech, B.V. BioCardia currently has limited commercial revenue and is still primarily funded through equity, grants, and partnering arrangements while it advances regulatory and clinical milestones.

## Products & services

• CardiAMP autologous cell therapy for ischemic heart failure
• Helix transendocardial delivery system
• Morph DNA steerable introducers / AVANCE
• Fusion imaging for cardiac biotherapeutic delivery and biopsy
• Biotherapeutic delivery partnering and commercialization support

- **Cell therapy programs** (10%) — Autologous and allogeneic cardiac cell therapy candidates being developed for heart failure and other cardiovascular indications.
- **Delivery systems and introducers** (45%) — Catheter-based tools used to deliver therapies into the heart, including Helix and Morph DNA/AVANCE products.
- **Fusion imaging technology** (15%) — Imaging systems and related intellectual property for guiding cardiac biotherapeutic delivery and biopsy.
- **Partnering and licensing** (20%) — Development, license, distribution, and option agreements that support commercialization and provide collaboration revenue.
- **Clinical and regulatory services** (10%) — Research, trial support, and regulatory development services provided to partners and for internal programs.

- CardiAMP autologous cell therapy for ischemic heart failure
- Helix transendocardial delivery system
- Morph DNA steerable introducers / AVANCE
- Fusion imaging for cardiac biotherapeutic delivery and biopsy
- Biotherapeutic delivery partnering and commercialization support

## Customers

BioCardia sells primarily to hospitals, interventional cardiologists, electrophysiologists, and clinical trial centers that use its catheter-based systems in cardiac procedures. Its commercial products are aimed at physicians performing transseptal and left-ventricular procedures, including mapping and treatment of atrial and ventricular tachyarrhythmias. The CardiAMP program is directed at patients with ischemic heart failure, but the commercial customer is the healthcare provider or trial sponsor rather than the patient directly. The company also works with biopharma and medtech partners that need delivery technology, imaging capability, or clinical development support to advance cardiac therapies. Because revenue is still limited, partner relationships and regulatory adoption are especially important customer channels.

- **Hospitals and cardiac procedure centers** (primary) — Buy delivery systems and introducers for transseptal and left-ventricular procedures because the tools support complex catheter access and therapy delivery.
- **Interventional cardiologists and electrophysiologists** (primary) — Use Morph DNA/AVANCE and Helix-based systems to improve catheter control in mapping, ablation, biopsy, and cell/gene delivery procedures.
- **Clinical trial investigators and research centers** (secondary) — Use CardiAMP and related systems in studies because BioCardia provides devices, protocol support, and commercialization-readiness services.
- **Strategic development partners** (secondary) — License or co-develop fusion imaging and delivery technologies to accelerate product development and market access.
- **Payers and reimbursement-dependent providers** (emerging) — Influence adoption of CardiAMP because procedure reimbursement affects whether hospitals can economically deploy the therapy.

- Hospitals and cath labs using catheter-based cardiac procedures
- Interventional cardiologists needing steerable introducers and delivery tools
- Electrophysiologists treating atrial and ventricular tachyarrhythmias
- Clinical trial centers enrolling heart failure and device studies
- Biopharma/medtech partners licensing delivery and imaging technology
- Healthcare systems adopting reimbursable procedures such as CardiAMP

## Geography

BioCardia is headquartered in the United States and its core commercial and clinical activity is centered there. The company’s CardiAMP heart failure trial enrolled patients at 18 centers in the United States and Canada, showing that North America is the main development footprint. BioCardia also has a meaningful Japan pathway, where it has held a positive preliminary consultation with PMDA and is preparing for a formal clinical consultation that could support market entry. Outside the U.S., the company has international partnering exposure through CART-Tech, B.V. in the Netherlands and broader worldwide rights for biotherapeutic delivery. Because the company is still pre-scale, geography matters mainly through regulatory approvals, trial execution, and partner commercialization rather than through a large installed sales base.

- United States is the main operating base and primary commercialization market
- Canada participates in CardiAMP clinical enrollment and evidence generation
- Japan is a key future market for potential regulatory approval and launch
- Netherlands exposure comes through the CART-Tech fusion imaging partnership
- Worldwide rights for biotherapeutic delivery expand partnering optionality
- Geography is driven more by trials and approvals than by current sales

## Strategy

BioCardia’s near-term strategy is to preserve liquidity while advancing its most promising clinical and commercial assets. The company is actively seeking additional capital through collaboration and licensing, debt, equity, or a mix of sources because current cash is not sufficient to fund planned operations beyond the near term. It is also trying to convert its technology platform into partner-supported commercialization, especially for Helix-based delivery systems and Morph products. On the clinical side, management is focused on progressing CardiAMP in the U.S. and Japan, where regulatory acceptance and reimbursement could create a path to broader adoption. The strategy is therefore a combination of financing, partnership monetization, and regulatory de-risking.

- **Secure additional financing** (short-term) — The company states current cash is not sufficient to fund planned expenditures beyond the near term, so financing is required to continue operations.
- **Advance CardiAMP regulatory pathway** (medium-term) — Clinical and regulatory progress is the main route to future product revenue and potential commercialization in heart failure.
- **Commercialize Morph DNA / AVANCE products** (short-term) — These FDA-cleared products are already available commercially and can generate nearer-term product revenue.
- **Monetize partnering and IP** (medium-term) — Partnerships can provide revenue, validation, and non-dilutive funding while the company remains development-stage.

- Raise near-term capital to fund operations and clinical development
- Use non-dilutive collaboration and licensing where possible
- Advance CardiAMP toward FDA and Japan regulatory pathways
- Commercialize Morph DNA/AVANCE steerable introducers
- Expand partner-led use of Helix delivery technology
- Build evidence for reimbursement-supported adoption
- Pursue fusion imaging commercialization with CART-Tech

## Risks

BioCardia faces substantial going-concern and financing risk because management has disclosed that existing cash is not sufficient to fund operations beyond the near term. The company also depends on clinical trial outcomes and regulatory acceptance for CardiAMP and other candidates, so setbacks in efficacy, safety, or approval timing could materially delay commercialization. As a small-cap development-stage issuer, it is exposed to Nasdaq continued listing risk, and delisting would make capital raising and partner confidence more difficult. More broadly, the business depends on reimbursement, physician adoption, and competition from alternative heart failure and electrophysiology technologies, all of which can slow uptake even after regulatory clearance. Because much of the value is tied to a few programs, any failure in one program can have an outsized effect on the company.

- **Insufficient cash to fund operations** [critical] — Management disclosed that current cash and expected financing are not enough to meet planned expenditures beyond the near term.
- **Clinical and regulatory failure** [high] — The company’s value depends on trial outcomes and FDA/PMDA acceptance for CardiAMP and related programs.
- **Nasdaq delisting** [high] — Non-compliance with listing requirements could reduce liquidity and impair access to capital.
- **Dilution from capital raises** [high] — The company expects to rely on equity or other financing that may be highly dilutive.
- **Commercial adoption and reimbursement uncertainty** [medium] — Even approved products need physician uptake and payer support to generate meaningful revenue.

- Near-term liquidity shortfall and going-concern pressure
- Dependence on clinical trial success for CardiAMP and other candidates
- Regulatory approval risk in the U.S. and Japan
- Nasdaq continued listing and potential delisting risk
- Dilution risk from repeated equity financing
- Reimbursement and physician adoption risk for new procedures
- Competition from other cardiac devices and cell therapy approaches

## Accounting

BioCardia’s reported results are highly sensitive to the timing of collaboration revenue, which can be irregular and depend on partner development activity rather than steady product shipments. The company has very limited current revenue, so small changes in collaboration milestones can create large quarter-to-quarter swings in reported sales and operating loss. Research and development expense is a major cost center and includes personnel, CRO fees, clinical trial materials, regulatory compliance, and licensed technology payments, all of which can vary materially as programs move through development stages. Because the company is development-stage and capital constrained, investors should also watch for judgments around going-concern disclosures, equity issuance costs, and the accounting impact of financing transactions. If commercialization expands, revenue recognition for licensing, distribution, and support arrangements will become more important and may involve significant judgment about performance obligations and timing.

- **Collaboration agreement revenue recognition** — Can cause large swings in reported revenue despite limited underlying commercial sales
- **Research and development cost timing** — Affects operating loss and comparability across periods
- **Going-concern and liquidity assessment** — Important for evaluating solvency, financing needs, and disclosure risk
- **Equity financing and issuance costs** — Can create dilution and affect net loss per share and equity balances

- Collaboration revenue is episodic and tied to partner activity
- Low revenue base makes quarterly comparisons volatile
- R&D spending depends on trial timing, CRO use, and regulatory work
- Licensed technology payments can affect expense recognition
- Going-concern and liquidity disclosures are highly relevant
- Future licensing and distribution deals may require judgment on revenue timing

---

*Last updated: 2026-08-11T04:46:23.755384+00:00*